Clinical TrialsInitial topline data from the Phase II MaGic study is expected sooner than previously guided, indicating progress in the clinical trial timeline.
Financial PerformanceDianthus reported higher-than-expected license revenue and a smaller net loss than consensus estimates for 1Q25.
Product DevelopmentDNTH103 has the potential to be a best-in-class complement inhibitor for generalized myasthenia gravis as a more convenient, self-administered treatment with no black box warning or REMS program.